With Pfizer’s stock down sharply, an activist investor is pushing for something new from the CEO who spurred the company to ...

Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value ...

Pfizer appointed a former chief executive officer at Vanguard, the drug giant's biggest investor, to its board on Tuesday as ...

As the fourth quarter of 2024 settles in, the narrative surrounding stocks on Wall Street is starting to shift.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

As a long-term holding, Pfizer should benefit from demographic trends driving increased healthcare spending globally. The ...

The activist investment firm Starboard Value has launched a proxy fight again Pfizer, questioning the company’s management ...

The corporate clash between Pfizer and Starboard Value heated up on Thursday when the activist investment firm pressed the ...

Fintel reports that on October 17, 2024, Bernstein initiated coverage of Pfizer (NYSE:PFE) with a Market Perform ...

Big Pharma is sticking to the recent molecular glue investment trend, with Pfizer now the latest major drugmaker to get in on ...

Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory ...

For fiscal 2024, analysts expect PFE to report an EPS of $2.66, up 44.6% from $1.84 in fiscal 2023 . Shares of PFE have ...